The Board of Indoco Remedies approved the re-appointment of Ms. Aditi Panandikar as Managing Director for a five-year term, ensuring leadership continuity for the pharmaceutical firm. The tenure is scheduled to commence on February 15, 2027, and conclude on February 14, 2032, pending final approval from shareholders at the company’s 79th Annual General Meeting. This decision follows recommendations from the Nomination and Remuneration Committee and was ratified during a board meeting held on July 28, 2026.

In a concurrent move to strengthen its senior management structure, the Board also appointed Mr. Sudhir Kadam as Senior Management Personnel, designated as Senior Vice President (Human Capital). His appointment took effect immediately on July 28, 2026, marking a strategic addition to the executive team responsible for human resources and organizational development.

Key Appointments

Ms. Panandikar, who holds a Master’s Degree in Pharmaceutical Administration from Ohio State University, brings over 30 years of experience in domestic marketing, human resources, technical functions including R&D and QA, and business development. As the daughter of Mr. Suresh G Kare, the Company’s Chairman, she has been integral to the organization’s techno-commercial strategy. The filing confirms that she is not debarred from holding office by SEBI or any other authority.

Mr. Kadam joins with a robust background in human resource management, holding a Master’s Degree in Management Studies (Human Resources) from Sydenham Institute of Management Studies and Research, Mumbai University. With three decades of experience across pharma, automotive, farm equipment, and engineering sectors, he will oversee strategic HR, talent management, and leadership development initiatives.

Regulatory Compliance

The announcements were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part-A of Schedule III. The disclosures align with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The Board meeting commenced at 10:45 a.m. and concluded at 11:45 a.m. on July 28, 2026.

Leadership Continuity

The re-appointment of Ms. Panandikar underscores the Board’s confidence in her long-standing leadership, which has spanned multiple critical functions within the company. Her dual expertise in pharmaceutical administration and commercial operations positions her to navigate the evolving regulatory and market landscapes in the healthcare sector. The simultaneous appointment of Mr. Kadam signals a focus on strengthening internal capabilities, particularly in talent acquisition and retention, which are vital for sustaining growth in a competitive industry. Shareholders will have the opportunity to vote on Ms. Panandikar’s re-appointment at the upcoming annual general meeting.

Indoco Remedies Limited reported a standalone net profit of ₹823.20 lakh for the quarter ended June 30, 2026, marking a significant recovery from the net loss of ₹280.70 lakh recorded in Q1FY26. The profitability surge was largely non-operational, driven by an exceptional gain of ₹9,734 lakh recognized from the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. Without this one-time item, the company incurred a pre-tax loss of ₹412 lakh, highlighting that core operational challenges persist despite the bottom-line improvement.

The Board of Directors, at its meeting held on July 28, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, pursuant to Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors M/s. Gokhale & Sathe, Chartered Accountants, who issued an unmodified opinion. Managing Director Aditi Panandikar attributed the revenue growth to resilient domestic formulation sales, noting steady progress in international formulations and API businesses despite a dynamic operating environment.

Standalone Performance

Standalone revenue from operations rose 5.8% year-on-year to ₹4,081.20 lakh, up from ₹3,856.10 lakh in Q1FY26. Domestic sales contributed ₹2,277.50 lakh, while exports accounted for ₹1,803.70 lakh. Total expenses remained high at ₹4,175.60 lakh, including employee benefits of ₹906.50 lakh and other expenses of ₹1,171.20 lakh, keeping operational profitability under pressure.

Consolidated Performance

On a consolidated basis, revenue from operations grew 8.2% year-on-year to ₹4,662.20 lakh, compared to ₹4,308.60 lakh in Q1FY26. Domestic sales reached ₹3,117.70 lakh and international sales stood at ₹1,544.50 lakh. Consolidated EBITDA improved significantly to ₹419 million from ₹103.50 million in the year-ago period, with EBITDA margin expanding to 9.00% from 2.41%. The consolidated loss before exceptional items narrowed to ₹196 million from a loss of ₹367 million in Q1FY26, reflecting improved operating leverage. Consolidated net profit attributable to equity shareholders was ₹649.90 lakh, compared to a loss of ₹357.90 lakh in Q1FY26, with the same exceptional gain of ₹9,734 lakh from the ophthalmic division sale supporting the turnaround. Finance costs stood at ₹282.90 lakh, while depreciation and amortization expenses increased to ₹345.30 lakh.

Key Financial Metrics

*Consolidated figures represent profit attributable to equity shareholders.

What the Numbers Show

The financial results reveal a stark divergence between operational performance and reported profitability. While the company achieved a headline net profit, its core operations continued to generate losses, with standalone profit before exceptional items and tax standing at a deficit of ₹412 lakh. This indicates that the recent profitability is entirely dependent on asset divestment rather than organic business growth. Furthermore, statutory auditors highlighted a material uncertainty regarding the going concern status of FPP Holding LLC, which continues to have a negative net worth of ₹3,822.60 lakh despite earning a net profit of ₹300.89 lakh in the quarter. Management has assessed no impairment provision necessary based on long-term business plans, but the erosion of net worth in this subsidiary remains a key risk factor for investors.